Compare CVS Health Corp (CVS) vs Xpeng Inc - ADR (XPEV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
CVS Health Corp vs Xpeng Inc - ADR — how do they compare? CVS Health Corp trades at $86.53 (market cap $112.29B), while Xpeng Inc - ADR trades at $10.08 (market cap $9.16B). The key difference: CVS Health Corp is far larger — about 12.3× Xpeng Inc - ADR's market cap, and CVS Health Corp pays a 3.03% dividend while Xpeng Inc - ADR pays none. Which is the better fit depends on your goals — on Pluang, investors hold CVS Health Corp for 83 Days and Xpeng Inc - ADR for 80 Days on average.
| CVS | XPEV | |
|---|---|---|
Market Cap | $112.29B | $9.16B |
Volume | 7,763,676 | 5,030,325 |
Sector | Health | Consumer Cyclical |
52-Week High | $110.60 | $28.07 |
52-Week Low | $70.08 | $9.25 |
Typical Hold Time | 83 Days | 80 Days |
Enterprise Value | $174.64B | $11.09B |
Dividend Yield | 3.03% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CVS Health trades at $87.95, up 1.76% on the day, with a bullish technical signal and strong analyst support. Recent earnings beats in Q1 and Q2 2026, alongside steady revenue growth to $402.07B in 2025, highlight operational strength. The stock's valuation appears attractive with a P/E of 23.17 and P/S of 0.27, while a consensus price target of $111.20 suggests significant upside potential. Positive news includes Aetna's 2027 Medicare plan enhancements and a declared quarterly dividend.
The outlook for CVS remains positive, driven by earnings momentum and strategic initiatives in healthcare services. Key risks include reimbursement pressures and regulatory scrutiny, but Wall Street's 85% buy rating and institutional interest underscore confidence. Investors should weigh the stock's growth prospects against margin volatility and debt levels, with the current price offering a favorable entry point relative to targets.
XPeng (XPEV) trades at $9.58, up 0.21% today, with a bearish technical signal despite oversold RSI readings. The company reported strong Q4 2025 earnings beat but missed Q1 and Q2 2026 expectations. Revenue grew to $76.72B in 2025, with net losses narrowing to -$1.14B. Recent news highlights XPeng's expansion into humanoid robotics and global vehicle launches, including the G9L SUV debut at the Paris Motor Show.
XPeng shows improving revenue growth and narrowing losses, but persistent unprofitability and high EV/EBITDA of 144.25 pose valuation concerns. Analyst consensus is bullish with a $17.55 price target, though execution risks in new robotics ventures and competitive EV market pressures remain key challenges for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About CVS Health Corp
Following its acquisition of Aetna in late 2018, CVS Health now provides an even more integrated healthcare-services offering for its members. Legacy CVS combined both the largest pharmacy benefit manager, processing over 2 billion adjusted claims annually, and a sizable pharmacy operation, including nearly 10,000 retail pharmacy locations primarily in the U.S. Adding a managed-care organization with 24 million medical members gives the company a strong position in the insurance industry and should help CVS better control overall healthcare costs for its clients.
Read more on CVS →About Xpeng Inc - ADR
Founded in 2015, XPeng is a leading Chinese smart electric vehicle, or EV, company that designs, develops, manufactures and markets EVs in China. Its products primarily target the growing base of technology-savvy middle-class consumers in the midrange to high-end segment in China's passenger vehicle market. The company sold over 98,000 EVs in 2021, accounting for about 3% of China's passenger new energy vehicle market. It is also a leader in autonomous driving technology.
Read more on XPEV →
